top of page
Browse by category
Search
GLP-1s not associated with an increased risk of pancreatitis
In a major new study, researchers from Intermountain Health in Salt Lake City have found that GLP-1 receptor agonists used by patients who have high triglycerides do not increase their risk of pancreatitis or adverse cardiac events, and for those who have never had pancreatitis, being on a GLP1RA medication led to a four times lower risk of developing the condition. "Pancreatitis is incredibly painful and can be deadly. Once you have a patient with acute pancreatitis, you wan
Significant increase of weight loss drugs before bariatric surgery
There has been a 16-fold increase in the use of weight loss drugs among patients before metabolic and bariatric surgery, signalling an...
MBS for weight loss shows greater long-term benefits than GLP-1 medicines
A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo metabolic and bariatric surgery (MBS)...
GLP-1 drugs shown cost-effective for knee osteoarthritis and obesity, but MBS may be the best option from a clinical and economic perspective
A study led by investigators at Mass General Brigham has found that adding semaglutide and tirzepatide to usual care represents a...
One in five people taking GLP-1s claim food tastes saltier or sweeter than before
Some individuals who are taking Ozempic, Wegovy or Mounjaro find that foods taste sweeter or saltier than before, according to research...
Study links GLP-1s with serious gastrointestinal conditions
Glucagon-like peptide-1 (GLP-1) agonists are associated with an increased risk of serious medical conditions including stomach paralysis,...
Browse by tag
bottom of page